CRYO-CELL International, Inc. (PK:CCEL)

Business Focus: Healthcare Facilities & Services

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 700 Brooker Creek Blvd Ste 1800
OLDSMAR FL 34677-2905
Tel: N/A
IR: See website
Key People
David I. Portnoy
Chairman of the Board, Co-Chief Executive Officer
Mark L. Portnoy
Co-Chief Executive Officer, Director
Jill M. Taymans
Chief Financial Officer, Vice President - Finance
Oleg Mikulinsky
Chief Information Officer
Business Overview
Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage. The Company's segments include cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of Prepacyte CB units, the processing technology used to process umbilical cord blood stem cells. The Company, in combination with its global affiliates, stores over 300,000 cord blood and cord tissue specimens around the world. The specimens are stored in commercially available cryogenic storage units at the facility in Oldsmar, Florida. The Company offers the cord tissue service in combination with the umbilical cord blood service. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals.
Financial Overview
For the six months ended 31 May 2019, CRYO-CELL International, Inc. revenues increased 22% to $15.6M. Net income before extraordinary items decreased 67% to $330K. Revenues reflect Processing and storage fees increase of 20% to $15M. Net income was offset by Selling, general and administrative expe increase of 4% to $7.4M (expense), Interest expense increase of 42% to $831K (expense).
Employees: 92 as of Nov 30, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $60.33M as of May 31, 2019
Annual revenue (TTM): $32.09M as of May 31, 2019
EBITDA (TTM): $6.05M as of May 31, 2019
Net annual income (TTM): $1.56M as of May 31, 2019
Free cash flow (TTM): $5.35M as of May 31, 2019
Net Debt Last Fiscal Year: $4.14M as of May 31, 2019
Shares outstanding: 7,803,333 as of Jul 9, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization